Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Psychedelic innovations and the crisis of psychopharmacology

Psychedelic innovations and the crisis of psychopharmacology In the 2010s, psychopharmacological research and development experienced a crisis: since no genuinely new drugs for the treatment of mental illness had been successfully developed for decades, major pharmaceutical corporations decided to disinvest their neuropsychopharmacology departments. At the same time, however, one branch of psychopharmacology began to boom. The FDA declared psychedelic-assisted psychotherapy a breakthrough therapy and hundreds of start-up companies began to compete for this potentially emerging health care market. The article looks at the case of psychedelic research to examine three different responses to the innovation crisis in psychopharmacology: (1) the resumption of pharmacopsychotherapy as a half-century old but previously marginalized and discontinued practice; (2) the continuation of self-experimentation as a simultaneously repressed and revitalized method of drug development; (3) computational drug design as a cutting-edge approach currently used to create non-psychedelic psychedelics that reduce psychiatric symptoms without any mind-altering effects. These responses point to conflicting imaginaries of innovation that envisage the future of psychopharmacology and thereby provide different diagnoses of its current predicament. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioSocieties Springer Journals

Psychedelic innovations and the crisis of psychopharmacology

BioSocieties , Volume OnlineFirst – Dec 15, 2022

Loading next page...
 
/lp/springer-journals/psychedelic-innovations-and-the-crisis-of-psychopharmacology-kHv0erB4RE

References (82)

Publisher
Springer Journals
Copyright
Copyright © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022
ISSN
1745-8552
eISSN
1745-8560
DOI
10.1057/s41292-022-00294-4
Publisher site
See Article on Publisher Site

Abstract

In the 2010s, psychopharmacological research and development experienced a crisis: since no genuinely new drugs for the treatment of mental illness had been successfully developed for decades, major pharmaceutical corporations decided to disinvest their neuropsychopharmacology departments. At the same time, however, one branch of psychopharmacology began to boom. The FDA declared psychedelic-assisted psychotherapy a breakthrough therapy and hundreds of start-up companies began to compete for this potentially emerging health care market. The article looks at the case of psychedelic research to examine three different responses to the innovation crisis in psychopharmacology: (1) the resumption of pharmacopsychotherapy as a half-century old but previously marginalized and discontinued practice; (2) the continuation of self-experimentation as a simultaneously repressed and revitalized method of drug development; (3) computational drug design as a cutting-edge approach currently used to create non-psychedelic psychedelics that reduce psychiatric symptoms without any mind-altering effects. These responses point to conflicting imaginaries of innovation that envisage the future of psychopharmacology and thereby provide different diagnoses of its current predicament.

Journal

BioSocietiesSpringer Journals

Published: Dec 15, 2022

Keywords: Psychopharmacology; Psychedelics; Psychedelic therapy; Innovation; Rational drug design; Self-experiment

There are no references for this article.